文献速递细胞病理与分子病理

7基因检测在不同Bethesda分类甲状腺细针穿刺中的评估:意大利南部多中心前瞻性研究

Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.
PubMed 文献 · Cancer Cytopathol · 2019-12-10

该多中心前瞻性研究对意大利南部7个中心的1172例甲状腺细针穿刺(FNA)按Bethesda系统分类,并用7基因检测BRAF、RAS、RET/PTC和PAX8/PPARg改变。在AUS/FLUS病例中,BRAFV600E和BRAF样突变阳性预测值为80%,RAS样改变为32.4%,提示不同突变类型对应不同手术管理。7基因 panel 有助于改善不确定FNA的术前风险分层。

要点

  • 7基因检测可改善不确定甲状腺FNA的术前风险分层。
  • AUS/FLUS中BRAFV600E和BRAF样突变阳性预测值为80%。
  • AUS/FLUS中RAS样改变阳性预测值为32.4%。

核心结论

  • 7基因 panel 检测可改善不确定甲状腺FNA的术前风险分层,尤其应考虑不同突变类型的生物学意义。
  • 突变阳性FNA的比例与各诊断类别的恶性风险相关。

研究设计与样本

  • 多中心前瞻性研究,纳入意大利南部7个中心的1172例常规甲状腺FNA。
  • FNA按Bethesda系统分类,每例标本行7基因检测,分子数据与可获得的组织学或细胞学随访比较。

主要发现

  • 在AUS/FLUS病例中,7基因检测证实BRAFV600E和BRAF样突变阳性预测值为80%。
  • 在AUS/FLUS病例中,RAS样改变的阳性预测值为32.4%。
  • 突变阳性FNA的比例与各诊断类别的恶性风险严格相关。

关键数值与推荐

  • AUS/FLUS病例中BRAFV600E和BRAF样突变阳性预测值为80%。
  • AUS/FLUS病例中RAS样改变阳性预测值为32.4%。

临床怎么用

  • 对不确定甲状腺FNA行7基因检测,结合突变类型进行术前风险分层和手术管理决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid fine-needle aspiration (FNA) is a reliable and cost-effective diagnostic tool for establishing the nature of thyroid nodules, although up to 30% of FNAs are still classified as "indeterminate." Molecular testing of FNAs could improve preoperative diagnosis, thereby reducing unnecessary surgery. In this multicenter prospective study the authors investigated, using a 7-gene assay, the distribution and diagnostic impact of BRAF, RAS, RET/PTC, and PAX8/PPARg, the most frequent genomic alterations occurring during thyroid oncogenesis. METHODS: In total, of 1172 routine FNAs from 7 centers in southern Italy were classified according to the Bethesda System for Reporting Thyroid Cytopathology. Each specimen was tested, and molecular data were compared with available histology or cytologic follow-up. RESULTS: In particular, for atypia of undetermined significance/follicular lesion of undetermined significance cases, the 7-gene test confirmed the high positive predictive value of BRAFV600E and BRAF-like mutations (80%) and the moderate positive predictive value of RAS-like alterations (32.4%), suggesting different surgical management, depending on the type of mutation. The rate of mutation-positive FNAs was strictly related to the risk of malignancy of each diagnostic class, supporting the identification of prognostically relevant diagnostic categories. CONCLUSIONS: The 7-gene panel test improves the preoperative risk stratification of indeterminate thyroid FNAs, especially when considering the biologic significance of the different types of mutations. Moreover, the rate of mutation-positive FNAs is related to the risk of malignancy of each diagnostic class.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Bellevicine C, Migliatico I, Sgariglia R, et al. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. Cancer Cytopathol. 2019. PMID: 31821746. doi:10.1002/cncy.22217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。